Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Evan Madill und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Multiple Sclerosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Academy of Neurology, Defense Human Resources Activity.
Abstract (Originalsprache)
Objective
Glial fibrillary acidic protein (GFAP) is expressed in astrocytes and may be a useful marker of non‐active progressive multiple sclerosis (MS). We evaluate serum GFAP (sGFAP) in a large cohort of MS patients to determine if it predicts progression independent of relapse activity (PIRA), future gait aid, and conversion to secondary progressive disease (SPMS).
Methods
Adults with clinically isolated syndrome or any subtype of MS who were listed in the Brigham MS Center Research Database and had at least one sGFAP result were included. All clinic visits following first sample were analyzed for PIRA, future gait aid, and conversion to SPMS. Future cognitive dysfunction and fatigue were evaluated as secondary outcomes.
Results
In total, 741 patients were included (average age: 42.3, average disease duration: 3.7 years, median EDSS: 2, and median follow‐up duration: 10.0 years). Of 643 patients (86.8%) without progressive disease at baseline, 15.9% developed SPMS. Among all 741, 50.5% had PIRA and 18.6% developed a gait aid requirement. sGFAP level predicted PIRA, future gait aid, and conversion to SPMS in univariable models ( p < 0.001,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Tanuja Chitnis
Förderung
- American Academy of Neurology
- Defense Human Resources Activity
Zitieren
APA
Madill, E., Healy, B. C., Molazadeh, N., Polgar-Turcsanyi, M., Glanz, B. I., Weiner, H. L., & Chitnis, T. (2024). Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52187
Vancouver
Madill E, Healy BC, Molazadeh N, Polgar-Turcsanyi M, Glanz BI, Weiner HL, et al. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52187
BibTeX
@article{Madill2024,
author = {Madill, Evan and Healy, Brian C and Molazadeh, Negar and Polgar-Turcsanyi, Mariann and Glanz, Bonnie I and Weiner, Howard L and Chitnis, Tanuja},
title = {Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52187}
}
EUVIMED